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Recently, Peter Jansen from the Depart-
ment of Gastroenterology and Hepatology 
and colleagues published a comprehensive re-
view about the mechanisms leading to choles-
tatic liver disease (Jansen et al., 2016). The 
authors describe the morphological changes 
at different topological domains of the biliary 
tree: while large bile ducts respond by en-
largement of ductular diameter to maximize 
their volume, intralobular bile ducts respond 
by branching and surface corrugation to opti-
mize their capacity to reabsorb bile salts (Var-
tak et al., 2016). A key mechanism in choles-
tatic liver disease is that the bile canaliculi in 
liver lobules become leaky, and toxic bile can 
get into contact with parenchymal cells lead-
ing to cytotoxicity and necrosis, a phenome-
non also named bile infarct. 
For toxicologists the perhaps most im-
portant lesson learned from this review is that 
cholestatic liver disease may have an ascend-
ing and a descending pathophysiology. For 
example primary sclerosing cholangitis and 
primary biliary cholangitis begins with early 
lesions ‘downstream’ in bile ducts which 
leads to bile salt-mediated injury ‘upstream’ 
in liver parenchyma. In contrast, most forms 
of drug induced cholestasis have a descending 
pathophysiology, where damage of hepato-
cytes represents the initial key event. 
Considering this classification it may be 
justified that in vitro systems to identify hepa-
totoxic compounds focus on hepatocytes 
(Miszczuk et al., 2015; Tolosa et al., 2015; 
Björnsson, 2015; Stöber, 2015a, b). Cur-
rently, large research programs focus on 
hepatocyte in vitro systems, either using func-
tional assays (Godoy et al., 2013; Reif et al., 
2016) or genome wide expression analysis 
(Schaap et al., 2015; Benet et al., 2014; Grin-
berg et al., 2014). 
However, it should be taken into account 
that also toxic cholestasis may in rare cases 
have an ascending pathophysiology. For ex-
ample, 3,5-diethoxycarbonyl-1,4-dihydrocol-
lidine (DDC) primarily causes damage to bile 
ducts, while parenchymal damage occurs as a 
secondary event (Fickert et al., 2007).  
Therefore, insufficient sensitivity in cur-
rently performed in vitro screens for hepato-
toxicity may be a consequence of neglecting 
compounds acting by an ascending patho-
physiology, where cholangiocytes and not 
hepatocytes represent primary targets. 
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